A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

Sponsor
Eisai Co., Ltd.
Study ID
NCT06793709
Status
Recruiting
Apply to this trial

Conditions

  • Biliary Tract Cancer

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • No Intervention — OTHER
    This is a non-interventional study.

Study Details

The primary purpose of this study is to investigate the safety of Tasfygo.

Key Dates

First listed
Jan 27, 2025
Start date
Jul 10, 2025
Status verified
Feb 2026
Primary completion
Nov 20, 2032
Completion
Nov 20, 2032

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Tasfygo tablet 35 milligrams (mg)

Primary Outcome Measure

Number of Participants With Adverse Drug Reactions [ Time Frame: Up to 1 year ]

Central Contacts

Related Studies